Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Multiple Sclerosis Journal · 2024
DOI: 10.1177/13524585241267211 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Izanne Roos und 45 weiteren Autor:innen. Beteiligte Einrichtung: CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, The Royal Melb…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Cladribine, Alemtuzumab, Fingolimod Hydrochloride. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Health and Medical Research Council, Multiple Sclerosis Australia.
Abstract (Originalsprache)
Background
Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking.
Objectives
To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting MS.
Methods
Patients with relapsing-remitting MS treated with cladribine, fingolimod, natalizumab, ocrelizumab or alemtuzumab were identified in the global MSBase cohort and two additional UK centres. Patients were followed for ⩾6/12 and had ⩾3 in-person disability assessments. Patients were matched using propensity score. Four pairwise analyses compared annualised relapse rates (ARRs) and disability outcomes.
Results
The eligible cohorts consisted of 853 (fingolimod), 464 (natalizumab), 1131 (ocrelizumab), 123 (alemtuzumab) or 493 (cladribine) patients. Cladribine was associated with a lower ARR than fingolimod (0.07 vs. 0.12, p = 0.006) and a higher ARR than natalizumab (0.10 vs. 0.06, p = 0.03), ocrelizumab (0.09 vs. 0.05, p = 0.008) and alemtuzumab (0.17 vs. 0.04, p < 0.001). Compared to cladribine, the risk of disability worsening did not differ in patients treated with fingolimod (hazard ratio (HR) 1.08, 95% confidence interval (CI) 0.47–2.47) or alemtuzumab (HR 0.73, 95% CI 0.26–2.07), but was lower for patients treated with natalizumab (HR 0.35, 95% CI 0.13–0.94) and ocrelizumab (HR 0.45, 95% CI 0.26–0.78). There was no evidence for a difference in disability improvement.
Conclusion
Cladribine is an effective therapy that can be viewed as a step up in effectiveness from fingolimod, but is less effective than the most potent intravenous MS therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
- Dokuz Eylul University, Konak, Izmir, Turkey.
- Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia/John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia.
- Immune Tolerance Laboratory Ingham Institute and Department of Medicine, UNSW, Sydney, NSW, Australia.
- Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait.
- Hospital Universitario Virgen Macarena, Sevilla, Spain.
ORCID-Profile: Izanne Roos, Sara Eichau Madueño, Anneke van der Walt, Nevin John, Michael Barnett, Jiwon Oh, Pierre Duquette, Emma Tallantyre, J William L Brown, Tomas Kalincik
Förderung
- National Health and Medical Research Council
- Multiple Sclerosis Australia
Zitieren
APA
Roos, I., Sharmin, S., Malpas, C., Ozakbas, S., Lechner-Scott, J., Hodgkinson, S., Alroughani, R., Eichau Madueño, S., Boz, C., van der Walt, A., Butzkueven, H., Buzzard, K., Skibina, O., Foschi, M., Grand'Maison, F., John, N., Grammond, P., Terzi, M., Prévost, J., …, & Kalincik, T. (2024). Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241267211
Vancouver
Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, et al. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241267211
BibTeX
@article{Roos2024,
author = {Roos, Izanne and Sharmin, Sifat and Malpas, Charles and Ozakbas, Serkan and Lechner-Scott, Jeannette and Hodgkinson, Suzanne and Alroughani, Raed and Eichau Madueño, Sara and Boz, Cavit and van der Walt, Anneke and Butzkueven, Helmut and Buzzard, Katherine and Skibina, Olga and Foschi, Matteo and Grand'Maison, Francois and John, Nevin and Grammond, Pierre and Terzi, Murat and Prévost, Julie and Barnett, Michael and Laureys, Guy and Van Hijfte, Liesbeth and Luis Sanchez-Menoyo, Jose and Blanco, Yolanda and Oh, Jiwon and McCombe, Pamela and Ramo Tello, Cristina and Soysal, Aysun and Prat, Alexandre and Duquette, Pierre and Yamout, Bassem I and Khoury, Samia and van Pesch, Vincent and Macdonell, Richard and José Sá, Maria and Slee, Mark and Kuhle, Jens and Maimone, Davide and Spitaleri, Daniele LA and Willekens, Barbara and Asmi, Abdallah Al and Tallantyre, Emma and Robertson, Neil P and Coles, Alasdair and L Brown, J William and Kalincik, Tomas},
title = {Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis},
journal = {Multiple Sclerosis Journal},
year = {2024},
doi = {10.1177/13524585241267211}
}
EUVIMED